Antoine Italiano Selected Research

onapristone

10/2020	Onapristone Extended Release: Safety Evaluation from Phase I-II Studies with an Emphasis on Hepatotoxicity.
1/2018	Phase I study of onapristone, a type I antiprogestin, in female patients with previously treated recurrent or metastatic progesterone receptor-expressing cancers.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Antoine Italiano Research Topics

Disease

117	Neoplasms (Cancer) 11/2022 - 06/2006
74	Sarcoma (Soft Tissue Sarcoma) 01/2022 - 05/2010
17	Neoplasm Metastasis (Metastasis) 01/2022 - 06/2006
16	Disease Progression 02/2022 - 08/2015
13	Gastrointestinal Stromal Tumors (Gastrointestinal Stromal Tumor) 06/2022 - 05/2012
13	Liposarcoma 01/2022 - 09/2009
11	Leiomyosarcoma 01/2022 - 06/2011
10	Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung) 02/2022 - 01/2007
10	Hemangiosarcoma (Angiosarcoma) 01/2022 - 01/2012
10	Osteosarcoma (Osteogenic Sarcoma) 01/2022 - 01/2013
10	Hypertension (High Blood Pressure) 01/2022 - 01/2016
9	Fatigue 01/2022 - 03/2014
9	Neutropenia 01/2022 - 03/2015
9	Breast Neoplasms (Breast Cancer) 01/2022 - 08/2011
8	Colorectal Neoplasms (Colorectal Cancer) 01/2021 - 01/2006
7	Nausea 01/2022 - 03/2014
5	Prostatic Neoplasms (Prostate Cancer) 01/2022 - 06/2009
5	Thrombocytopenia (Thrombopenia) 01/2022 - 05/2015
5	Carcinoma (Carcinomatosis) 01/2022 - 06/2014
5	Synovial Sarcoma (Synovioma) 01/2021 - 04/2016
5	Aggressive Fibromatosis (Desmoid) 12/2020 - 04/2012
5	Carcinogenesis 09/2017 - 06/2011
4	Asthenia 01/2021 - 08/2015
4	Melanoma (Melanoma, Malignant) 01/2021 - 08/2015
4	Myxoid Liposarcoma 01/2021 - 04/2016
4	Cholangiocarcinoma 01/2020 - 08/2015
3	Biliary Tract Neoplasms (Biliary Tract Cancer) 01/2022 - 01/2020
3	Endometrial Neoplasms (Endometrial Cancer) 01/2022 - 01/2018
3	Diarrhea 01/2022 - 01/2021
3	Vomiting 01/2022 - 03/2014
3	Febrile Neutropenia 01/2022 - 11/2007
3	Ewing Sarcoma (Sarcoma, Ewing) 01/2020 - 04/2016
3	Anaplastic Thyroid Carcinoma 01/2020 - 07/2015
3	Sepsis (Septicemia) 03/2019 - 11/2007
3	Pigmented Villonodular Synovitis 01/2018 - 03/2012
2	Squamous Cell Carcinoma (Epidermoid Carcinoma) 01/2022 - 01/2022
2	Headache (Headaches) 01/2022 - 01/2018

Drug/Important Bio-Agent (IBA)

15	Imatinib Mesylate (Gleevec)FDA Link 05/2022 - 01/2008
15	TrabectedinIBA 01/2022 - 08/2011
15	Biomarkers (Surrogate Marker)IBA 01/2022 - 10/2009
11	Doxorubicin (Adriamycin)FDA LinkGeneric 01/2022 - 07/2012
11	Pharmaceutical PreparationsIBA 01/2022 - 01/2012
10	Biological ProductsIBA 01/2022 - 09/2009
10	Immune Checkpoint InhibitorsIBA 12/2021 - 09/2016
10	AnthracyclinesIBA 01/2021 - 07/2012
9	regorafenibIBA 01/2022 - 11/2015
8	Phosphotransferases (Kinase)IBA 03/2022 - 11/2020
8	LigandsIBA 02/2022 - 01/2016
8	Sunitinib (Sutent)FDA Link 01/2020 - 05/2012
7	pembrolizumabIBA 01/2022 - 10/2019
7	pazopanib FDA Link 01/2022 - 01/2016
7	AntibodiesIBA 01/2022 - 05/2010
7	Ifosfamide FDA LinkGeneric 04/2021 - 01/2013
7	ErbB Receptors (EGF Receptor)IBA 06/2010 - 01/2006
6	Tyrosine Kinase InhibitorsIBA 05/2022 - 12/2012
6	larotrectinibIBA 03/2022 - 11/2020
6	Alanine Transaminase (SGPT)IBA 10/2020 - 03/2015
5	TropomyosinIBA 03/2022 - 11/2020
5	Aspartate Aminotransferases (Aspartate Transaminase)IBA 01/2022 - 03/2015
5	B7-H1 AntigenIBA 01/2022 - 10/2019
5	Proteins (Proteins, Gene)FDA Link 10/2020 - 09/2012
5	Paclitaxel (Taxol)FDA LinkGeneric 10/2018 - 04/2005
4	Anaplastic Lymphoma KinaseIBA 10/2021 - 07/2015
4	CrizotinibIBA 10/2021 - 07/2015
4	Methotrexate (Mexate)FDA LinkGeneric 04/2021 - 01/2013
4	Mitogen-Activated Protein Kinase Kinases (MEKs)IBA 01/2021 - 01/2017
4	erdafitinibIBA 12/2020 - 10/2015
4	Macrophage Colony-Stimulating FactorIBA 01/2018 - 08/2015
3	cabozantinibIBA 06/2022 - 01/2020
3	budigalimabIBA 02/2022 - 01/2021
3	Indoleamine-Pyrrole 2,3,-Dioxygenase (Indoleamine 2,3 Dioxygenase)IBA 01/2022 - 01/2015
3	EnzymesIBA 01/2022 - 01/2015
3	Tryptophan (L-Tryptophan)FDA Link 01/2022 - 01/2015
3	KynurenineIBA 01/2022 - 01/2015
3	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 01/2021 - 09/2014
3	tazemetostatIBA 11/2020 - 01/2018
3	Poly(ADP-ribose) Polymerase InhibitorsIBA 06/2020 - 11/2017
3	Gemcitabine FDA Link 01/2020 - 01/2017
3	eribulin FDA Link 10/2017 - 04/2016
3	ParaffinIBA 01/2017 - 02/2008
3	Cetuximab (Erbitux)FDA Link 08/2015 - 02/2008
3	Sorafenib (BAY 43-9006)FDA Link 09/2014 - 01/2012
2	entrectinibIBA 03/2022 - 01/2022
2	durvalumabIBA 01/2022 - 01/2020
2	Alanine (L-Alanine)FDA Link 01/2022 - 10/2020
2	avelumabIBA 01/2022 - 01/2021
2	Nuclear Proteins (Protein, Nuclear)IBA 01/2022 - 12/2017
2	PlatinumIBA 01/2022 - 11/2016
2	Tryptophan Oxygenase (Tryptophan 2,3 Dioxygenase)IBA 01/2022 - 01/2015

Therapy/Procedure

52	Therapeutics 01/2022 - 02/2008
44	Drug Therapy (Chemotherapy) 01/2022 - 11/2007
12	Immunotherapy 01/2022 - 01/2015
10	Radiotherapy 02/2021 - 06/2012
7	Neoadjuvant Therapy 01/2021 - 06/2012
4	Aftercare (After-Treatment) 01/2020 - 09/2013
3	Duration of Therapy 02/2022 - 08/2015
3	Castration 01/2022 - 06/2009
3	Intravenous Infusions 01/2020 - 05/2015
3	Combination Drug Therapy (Combination Chemotherapy) 01/2019 - 12/2014
2	Drug Tapering 01/2022 - 01/2020